- Home
- PHI vs RNA Comparison
PHI vs RNA Comparison
Compare PHI & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHI
- RNA
- Stock Information
- Founded
- PHI 1928
- RNA 2012
- Country
- PHI Philippines
- RNA United States
- Employees
- PHI N/A
- RNA N/A
- Industry
- PHI Telecommunications Equipment
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- PHI Telecommunications
- RNA Health Care
- Exchange
- PHI Nasdaq
- RNA Nasdaq
- Market Cap
- PHI 5.0B
- RNA 4.0B
- IPO Year
- PHI 1953
- RNA 2020
- Fundamental
- Price
- PHI $22.64
- RNA $44.03
- Analyst Decision
- PHI
- RNA Strong Buy
- Analyst Count
- PHI 0
- RNA 15
- Target Price
- PHI N/A
- RNA $68.40
- AVG Volume (30 Days)
- PHI 59.2K
- RNA 3.8M
- Earning Date
- PHI 08-12-2025
- RNA 08-07-2025
- Dividend Yield
- PHI 5.52%
- RNA N/A
- EPS Growth
- PHI 20.57
- RNA N/A
- EPS
- PHI 2.62
- RNA N/A
- Revenue
- PHI $3,879,170,293.00
- RNA $10,729,000.00
- Revenue This Year
- PHI $3.36
- RNA N/A
- Revenue Next Year
- PHI $2.58
- RNA $196.18
- P/E Ratio
- PHI $8.56
- RNA N/A
- Revenue Growth
- PHI 2.02
- RNA 1.23
- 52 Week Low
- PHI $20.29
- RNA $21.51
- 52 Week High
- PHI $29.05
- RNA $56.00
- Technical
- Relative Strength Index (RSI)
- PHI 47.33
- RNA 62.74
- Support Level
- PHI $22.74
- RNA $45.06
- Resistance Level
- PHI $22.92
- RNA $47.50
- Average True Range (ATR)
- PHI 0.32
- RNA 2.67
- MACD
- PHI -0.08
- RNA 0.02
- Stochastic Oscillator
- PHI 7.69
- RNA 68.03
About PHI PLDT Inc. Sponsored ADR
PLDT Inc is the telecommunications carrier in the Philippines. The company's business activities include three business units: Wireless, Fixed Line and Others. The wireless segment consists of mobile telecommunications services provided by Smart and DMPI, and Fixed-line telecommunications services mainly provided by PLDT. It also provides fixed-line services through PLDT's subsidiaries.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.